By Olivia Bugault

Bayer AG (BAYN.XE) said Friday that the European Union's Committee for Medicinal Products for Human Use has given a positive opinion on its darolutamide medicine as a new treatment for men with a particular type of prostate cancer.

The compound--jointly developed with ORION Corp. (271560.SE)--is recommended for men with non-metastatic castration-resistant prostate cancer who have a high risk of developing metastatic disease, the pharmaceutical firm said.

In most cases a recommendation leads to marketing approval. Bayer said that it expects a decision to be made in the coming months.

Write to Olivia Bugault at olivia.bugault@wsj.com

(END) Dow Jones Newswires

January 31, 2020 07:04 ET (12:04 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Grafico Azioni Bayer (TG:BAYN)
Storico
Da Apr 2024 a Mag 2024 Clicca qui per i Grafici di Bayer
Grafico Azioni Bayer (TG:BAYN)
Storico
Da Mag 2023 a Mag 2024 Clicca qui per i Grafici di Bayer